ATAI Life Sciences NV (ATAI Life Sciences NV) EV-to-Revenue : 497.75 (As of May. 11, 2024)

View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ATAI Life Sciences NV's enterprise value is $156.30 Mil. ATAI Life Sciences NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.31 Mil. Therefore, ATAI Life Sciences NV's EV-to-Revenue for today is 497.75.

The historical rank and industry rank for ATAI Life Sciences NV's EV-to-Revenue or its related term are showing as below:

ATAI' s EV-to-Revenue Range Over the Past 10 Years
Min: -254.67 Med: 192.85 Max: 989.79
Current: 497.75

During the past 5 years, the highest EV-to-Revenue of ATAI Life Sciences NV was 989.79. The lowest was -254.67. And the median was 192.85.

ATAI's EV-to-Revenue is ranked worse than
92.97% of 1039 companies
in the Biotechnology industry
Industry Median: 8.37 vs ATAI: 497.75

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-11), ATAI Life Sciences NV's stock price is $1.89. ATAI Life Sciences NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, ATAI Life Sciences NV's PS Ratio for today is 1,890.00.

ATAI Life Sciences NV EV-to-Revenue Historical Data

The historical data trend for ATAI Life Sciences NV's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV EV-to-Revenue Chart

ATAI Life Sciences NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

42.87

809.65

239.92

ATAI Life Sciences NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial												809.65	264.38	287.22	72.05	239.92

Competitive Comparison of ATAI Life Sciences NV's EV-to-Revenue

For the Biotechnology subindustry, ATAI Life Sciences NV's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ATAI Life Sciences NV's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where ATAI Life Sciences NV's EV-to-Revenue falls into.

ATAI Life Sciences NV EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

ATAI Life Sciences NV's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	156.295	/	0.314
	=	497.75

ATAI Life Sciences NV's current Enterprise Value is $156.30 Mil.
ATAI Life Sciences NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.31 Mil.

ATAI Life Sciences NV (NAS:ATAI) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

ATAI Life Sciences NV's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.89	/	0.001
	=	1,890.00

ATAI Life Sciences NV's share price for today is $1.89.
ATAI Life Sciences NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

ATAI Life Sciences NV EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ATAI Life Sciences NV (ATAI Life Sciences NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (NAS:ATAI) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

ATAI:Mexico 9VC:Germany

Address

Wallstraße 16, Berlin, BB, DEU, 10179

Website

https://www.atai.life

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Executives

Florian Brand	officer: See Remarks	C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Anne Nagengast Johnson	officer: Chief Accounting Officer	C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Apeiron Investment Group Ltd.	10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Sahil Kirpekar	officer: Chief Business Officer	C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Stephen Bardin	officer: Chief Financial Officer	C/O ATAI LIFE SCIENCES N.V., KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Gregory L Weaver	officer: Chief Financial Officer	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Andrea Heslin Smiley	director	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Michael Auerbach	director	158 HESTER STREET, APT 7F, NEW YORK NY 10013
Amir H Kalali	director	4350 EXECUTIVE DRIVE SUITE 325, SAN DIEGO CA 92121
Christian Angermayer	director, 10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Rosnay Alexis De	director	C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Srinivas Rao	officer: See Remarks	C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Sabrina Martucci Johnson	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Camm	director	C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Presight Ii, Lp	10 percent owner	C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014